IRB #

STUDY00019330

Title

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Principal Investigator

Jeremy Cetnar

Study Purpose

To assess the safety, efficacy, and tolerability of using lenvatinib and pembrolizumab together in patients with Non-Small Cell Lung Cancer (NSCLC)

Medical Condition(s)

Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

1. Male or female over 18 years old
2. Stage IV Non-Small Cell Lung Cancer

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug (s) until the disease progresses, treatment is no longer tolerable, or the participant and/or the study investigator decide to stop treatment.

After finishing treatment, the study investigator will continue to watch participants for side effects and follow participant's condition until study completion.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Merck Sharp & Dohme Corp

Recruitment End

11/30/2023

Compensation Provided

No


Go Back